Ascendis Pharma A/S
ASND173.500USD
+6.720+4.03%
Cierre 07/31, 16:00（ET）Cotizaciones retrasadas 15 min
10.58BCap. mercado
PérdidaP/E TTM
Más Datos de Ascendis Pharma A/S Compañía
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Información de la empresa
Símbolo de cotizaciónASND
Nombre de la empresaAscendis Pharma A/S
Fecha de salida a bolsaJan 28, 2015
Fundada en2006
Director ejecutivoMr. Jan Moller Mikkelsen
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJan 28
DirecciónTuborg Boulevard 12
CiudadHELLERUP
Bolsa de valoresNASDAQ Global Select Consolidated
PaísDenmark
Código postal2900
Teléfono4570222244
Sitio Webhttps://ascendispharma.dk/
Símbolo de cotizaciónASND
Fecha de salida a bolsaJan 28, 2015
Fundada en2006
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Desglose de ingresos
Divisa: EURActualizado: dom., 6 de jul
Divisa: EURActualizado: dom., 6 de jul
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioEUR
Nombre
Ganancia
Proporción
Commercial sale of products
96.03M
95.12%
Rendering of services
3.52M
3.49%
License
1.40M
1.39%
Por regiónEUR
Nombre
Ganancia
Proporción
North America
73.69M
72.99%
Europe
21.33M
21.13%
Rest of world
5.94M
5.88%
Por negocio
Por región
Por negocioEUR
Nombre
Ganancia
Proporción
Commercial sale of products
96.03M
95.12%
Rendering of services
3.52M
3.49%
License
1.40M
1.39%
Estadísticas de accionistas
Actualizado: mié., 23 de jul
Actualizado: mié., 23 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
17.03%
Westfield Capital Management Company, L.P.
9.08%
Avoro Capital Advisors LLC
8.64%
Janus Henderson Investors
7.43%
Fidelity Management & Research Company LLC
7.13%
Other
50.69%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
17.03%
Westfield Capital Management Company, L.P.
9.08%
Avoro Capital Advisors LLC
8.64%
Janus Henderson Investors
7.43%
Fidelity Management & Research Company LLC
7.13%
Other
50.69%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
41.95%
Investment Advisor
39.67%
Venture Capital
17.38%
Hedge Fund
8.82%
Research Firm
4.70%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Pension Fund
0.36%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
499
70.49M
116.76%
-1.46M
2025Q1
513
68.89M
114.10%
-3.55M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
10.28M
17.03%
+168.75K
+1.67%
Mar 31, 2025
Westfield Capital Management Company, L.P.
5.48M
9.08%
-48.98K
-0.89%
Mar 31, 2025
Avoro Capital Advisors LLC
5.22M
8.64%
+114.94K
+2.25%
Mar 31, 2025
Janus Henderson Investors
4.49M
7.43%
+106.57K
+2.43%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.30M
7.13%
-52.57K
-1.21%
Mar 31, 2025
Artisan Partners Limited Partnership
4.26M
7.05%
-193.79K
-4.35%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.05M
5.06%
+328.28K
+12.04%
Mar 31, 2025
Capital International Investors
2.87M
4.76%
+11.54K
+0.40%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.26M
3.74%
-27.11K
-1.19%
Mar 31, 2025
MFS Investment Management
1.87M
3.1%
+9.63K
+0.52%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Harbor Health Care ETF
18.34%
AdvisorShares Dorsey Wright ADR ETF
2.58%
American Century Focused Dynamic Growth ETF
2.27%
BNY Mellon Innovators ETF
2.26%
Virtus LifeSci Biotech Products ETF
2.01%
Tema Heart & Health ETF
1.25%
ProShares Ultra Nasdaq Biotechnology
1.19%
Invesco Nasdaq Biotechnology ETF
1.11%
Main Thematic Innovation ETF
0.76%
Putnam Sustainable Future ETF
0.75%
Ver más
Harbor Health Care ETF
Proporción18.34%
AdvisorShares Dorsey Wright ADR ETF
Proporción2.58%
American Century Focused Dynamic Growth ETF
Proporción2.27%
BNY Mellon Innovators ETF
Proporción2.26%
Virtus LifeSci Biotech Products ETF
Proporción2.01%
Tema Heart & Health ETF
Proporción1.25%
ProShares Ultra Nasdaq Biotechnology
Proporción1.19%
Invesco Nasdaq Biotechnology ETF
Proporción1.11%
Main Thematic Innovation ETF
Proporción0.76%
Putnam Sustainable Future ETF
Proporción0.75%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
